Insights and Analysis
AI-washing – when AI hype becomes a litigation risk
Xin Tao
Partner Global Regulatory
Languages
Mandarin, English, Chinese
-
Overview
-
Experience
-
Credentials
-
Insights and events
Chambers USAXin is very passionate about what he is working on, very experienced in the field and always considerate of what clients are thinking.
Xin Tao advises life sciences and technology companies and investors on high-stake regulatory compliance, government enforcement, and strategic collaboration and transaction matters, particularly those involving China outbound investment and global business expansion.
As former research scientist, Xin draws on his scientific training and legal judgment to deliver practical, creative, and commercially grounded advice on clients’ most critical business challenges. His practice spans pharmaceuticals, medical devices, food, cosmetics, and consumer technologies.
Xin has extensive experience advising clients on U.S and EU regulatory compliance and government enforcement issues, including matters involving the U.S. Congress, U.S. Department of Justice (DOJ), U.S. Food and Drug Administration (FDA), Federal Trade Commission (FTC), and U.S. Consumer Product Safety Commission (CPSC). He is adept at leading multidisciplinary teams across jurisdictions on handling cross-border regulatory strategy, government investigations, product safety, national security, and consumer protection issues. His ability to align differing business expectations and regulatory approaches across jurisdictions positions him as a trusted advisor to international companies facing complex market entry and investment decisions. Xin also routinely advises on strategic collaborations, cross-border transactions, and product launch in the life sciences and technology industries.
Chambers USAXin is very passionate about what he is working on, very experienced in the field and always considerate of what clients are thinking.
Representative experience
Advised Takeda Pharmaceutical Company on a landmark multi-asset global collaboration with Innovent Biologics for the co-development and commercialization of oncology therapies*
Advised Takeda Pharmaceutical Company in connection with its worldwide license and collaboration agreement with Protagonist Therapeutics, Inc., for the development and commercialization of rusfertide*
Advised Shanghai Zhenhua Heavy Industries Co., Ltd., a world-leading heavy equipment manufacturer, in relation to a high-profile US congressional investigation concerning national security issues*
Advised Duality Biologics, a clinical-stage biotechnology company developing antibody-drug conjugate therapeutics, on its cross-border clinical collaboration with AstraZeneca relating to ADC programs*
Advised a leading Asian e-commerce platform company on U.S. regulatory strategy and broader global compliance issues relating to consumer products*
Advised a leading Chinese pharmaceutical company on successful remediation and enforcement strategy following an FDA Warning Letter for drug cGMP violations, resulting in removal from Import Alert*
Advised several leading US and European pharmaceutical companies on China regulatory considerations for early-stage clinical development, including investigator-initiated trials (IITs)*
Advised a pharmaceutical company on regulatory response to enforcement action by National Medical Products Administration and the implementation of the drug recall in China by a multinational company*
Advised a leading Asian food and beverage company in achieving de-escalation of FDA enforcement action by obtaining agency concurrence for a voluntary market withdrawal instead of a nationwide recall*
Advised Mission Barns, an innovative food technology company, on obtaining the world’s first regulatory clearance for cultivated pork products from FDA*
Advised a leading Asian medical device company on an internal compliance investigation and FDA engagement to obtain agency concurrence for voluntary corrective actions addressing potential violations*
*Matter handled prior to joining Hogan Lovells.
Credentials
Education
- J.D., Georgetown University Law Center, 2012
- M.S., Texas A&M University, 2009
- B.S. Biotechnology, Shanghai Jiaotong University, 2006
Bar admissions and qualifications
- District of Columbia
Recognition
Publications
News
Press releases
28 April 2026